In the ARREST trial [3], the primary endpoint was the time to bacteriologically confirmed treatment failure, disease recurrence or death. In randomized controlled trials (RCTs), to assess the efficacy of an intervention on a time-to-event endpoint, the hazard ratio (HR) is routinely used. ...
Their primary CEs are, respectively, progression-free survival (time to progression of disease or death) and the composite of bacteriologically confirmed treatment failure or Staphilococcus aureus related death by 12 weeks. Results: For a target power of 0.80, the simulation study provided mean (...
the effect of measurement errors on predicting cardiovascular events or death based on serum concentration of cholesterol and on progression of chronic kidney disease to kidney failure based on serum concentrations of albumin, bicarbonate, calcium and phosphate, and urine albumin/creatinine-ratio. Results...
It is important to consider the Hazard ratio as well as the median OS, as the Hazard ratio evaluates the risk of death for the whole population—rather than the median patient—and may show significant benefit, even when there is little difference in median OS....
The Progression of Vulnerability framework (Figure 2) attempts to model the relationships among these processes and the intersection of scale over time. Root causes may be remote geographically from the local site of vulnerability, such as an investment decision by a distant corporation. Th...
Survival analysis is a statistical approach for analyzing time-to-event data, such as the time until death, recurrence of disease, or progression of disease. Survival analysis is commonly used to understand the dynamic nature of the disease and its treatment, to identify prognostic factors, and ...
These results marked a significant improvement compared to the patients in the chemotherapy arm (12.1 months vs. 7.8 months; hazard ratio, 0.64; 95% confidence interval, 0.44 to 0.93; P=0.005) (1). Moreover, treatment with erdafitinib showed an improvement in median PFS compared to ...
Patients with HER2+ hormone receptor-positive (HR+ (hormone receptor-positive); ER+ (estrogen receptor-positive) or PR+ (progesterone receptor-positive)) disease had a significantly better DFS than patients with HER2+ HR- (ER-/PR-) disease (hazard ratio 0.72, P = 0.02). This ...
In the ARREST trial [3], the primary endpoint was the time to bacterio- logically confirmed treatment failure, disease recurrence or death. In randomized controlled trials (RCTs), to assess the efficacy of an intervention on a time-to-event endpoint, the hazard ratio (HR) is routinely used...
In the ARREST trial [3], the primary endpoint was the time to bacterio- logically confirmed treatment failure, disease recurrence or death. In randomized controlled trials (RCTs), to assess the efficacy of an intervention on a time-to-event endpoint, the hazard ratio (HR) is routinely used...